Restoration of G1/S arrest in E1A+c-Ha-ras-transformed cells by Bcl-2 overexpression

Cell Cycle

Volumn 3, Issue 11, 2004, Pages 1427-1432

  Nelyudova, Anna M ^a   Tararova, Nataliya D ^a   Aksenov, Nikolay D ^a   Pospelov, Valery A ^a   Pospelova, Tatiana V ^a  

^a INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Bcl 2; c Ha ras; E1A; G1 S arrest; MAP kinases; p21 Waf 1

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CDKN1A PROTEIN, RAT; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DNA; P21 ACTIVATED KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; GENOTOXICITY; IONIZING RADIATION; NONHUMAN; RAT; ANIMAL; CELL CYCLE S PHASE; CELL LINE; COMPARATIVE STUDY; CULTURE MEDIUM; DNA DAMAGE; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; METABOLISM; RADIATION EXPOSURE; TIME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CULTURE MEDIA, SERUM-FREE; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA; DNA DAMAGE; DOXORUBICIN; G1 PHASE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION, IONIZING; RATS; S PHASE; TIME FACTORS; TRANSFECTION;

EID: 14644388712     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.11.1204     Document Type: Article

References (40)

1. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize preB cells. Nature 1988; 335:440-2.
2. Quinn LM, Richardson H. Bcl-2 in cell cycle regulation. Cell Cycle 2004; 3:7-9.
3. O'Reilly LA, Harris AW, Tarlinton DW, Corcoran LM, Strasser A. Expression of a bcl-2 transgene reduces proliferation and shows turnover of developing B lymphocytes in vivo. J Immunol 1997; 159:2301-11.
4. Pietenpol JA, Papadopoulos N, Markowitz S, Wilson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res 1994; 54:3714-7.
5. de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A, Perret C. Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res 1999; 59:5017-22.
6. Furth PA, Bar-Peled U, Li M, Lewis A, Laucirica R, Jager R, Weiher H, Russell RG. Loss of anti-mitotic effect of Bcl-2 with retention of antiapoptotic activity during tumor progression in a mouse model. Oncogene 1999; 18:6589-96.
7. Murphy KL, Kittrell FS, Gay JP, Jager R, Medina D, Rosen JM. Bcl-2 expression delays mammary tumor development in dimethylbenz(a)anthracene-treated transgenic mice. Oncogene 1999; 18:6597-604.
8. 1 phase in continuous chemostat cultures of hybridoma cells. Biotechnol Bioeng 1999; 64:174-86.
9. Rossiter H, Beissert S, Mayer C, Schon MP, Wienrich BG, Tschachler E, Kupper TS. Targeted expression of bcl-2 to murine basal epidermal keratinocytes results in paradoxical retardation of ultraviolet- and chemical-induced tumorigenesis. Cancer Res 2001; 61:3619-26.
10. Vail ME, Chaisson ML, Thompson J, Fausto N. Bcl-2 expression delays hepatocyte cell cycle progression during liver regeneration. Oncogene 2002; 21:1548-55.
11. Marvel J, Perkins GR, Lopez-Rivas A, Collins MKL. Growth factor starvation of bcl-2 overexpressing murine bone marrow cells induced refractoriness of IL-3 stimulation of proliferation. Oncogene 1994; 9:1117-22.
12. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15:6979-90.
13. Huang DCS, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16:4628-38.
14. Vairo G, Innes KM, Adams JM. Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13:1511-9.
15. 1 cyclin-dependent kinases. Oncogene 2002; 21:7765-75.
16. L/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J 2003; 22:5459-70.
17. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, Ewen ME, Koff A, Adams JM. Bcl-2 retards cell cycle entry through p27 kip1, pRb relative p130, and altered E2F regulation. Mol Cell Biol 2000; 20:4745-53.
18. Borner C. Diminished cell proliferation associated with the death-protective activity of Bcl-2. J Biol Chem 1996; 271:12695-8.
19. Uhlmann EJ, D'Sa-Eipper C, Subramanian T, Wagner AJ, Hay N, Chinnadurai G. Deletion of a nonconserved region of Bcl-2 confers a novel gain of function: Suppression of apoptosis with concomitant cell proliferation. Cancer Res 1996; 56:2506-9.
20. Bulavin DV, Tararova ND, Aksenov ND, Pospelov VA, Pospelova TV. Deregulation of p53/p21Cip1/Waf1 pathway contributes to polyploidy and apoptosis of E1A+c-Ha-ras transformed cells after gamma-irradiation. Oncogene 1999; 18:5611-9.
21. Buchou T, Kranenburg O, van Dam H, Roelen D, Zantema A, Hall FL, van der Eb A. Increased cyclin A and decreased cyclin D levels in adenovirus 5 E1A-transformed rodent cell lines. Oncogene 1993; 8:1765-73.
22. 1-phase progression. Genes Dev 1999; 13:1501-12.
23. Blanchard DA, Mouhamad S, Auffredou MT, Pesty A, Bertoglio J, Leca G, Vazquez A. Cdk2 associates with MAP kinase in vivo and its nuclear translocation is dependent on MAP kinase activation in IL-2-dependent Kit 225 T lymphocytes. Oncogene 2000; 19:4184-9.
24. Waf1/Cip1/Sdi1 on cellular gene expresion: Implications for carcinogenesis, senescence, and age-related deseases. Proc Natl Acad Sci USA 2000; 97:4291-6.
25. Delavaine L, La Thangue NB. Control of E2F activity by p21Waf1/Cip1. Oncogene 1999; 18:5381-5392.
26. cip1/waf1/sdi1 in DNA replication and transcription. J Biol Chem 2000; 275:10477-83.
27. Waf-1/Cip-1 induction of p300 transactivation. Mol Cell Biol 2000; 20:2676-86.
28. WAF1/CIP1 is core promoter specific and cyclin dependent kinase independent. Cell Cycle 2002; 1:343-50.
29. waf1/cip1/sdi1: Role of NFκB and effect of nonsteroidal anti-inflammatory drugs. Cell Cycle 2004; 3:931-40.
30. Shim J, Lee H, Park J, Kim H, Choi E-J. A nonenzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996; 381:804-6.
31. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, Fornace AJ Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 1999; 18:6845-54.
32. Wang S, Nath N, Minden A, Chellappan S. Regulation of Rb and E2F by signal transduction cascades: Divergent effects of JNK1 and p38 kinases. EMBO J 1999; 18:1559-70.
33. Haq R, Brenton JD, Takahashi M, Finan D, Rottapel R, Zanke B. Constitutive p38HOG mitogen-activated protein kinase activation induces permanent cell cycle arrest and senescence. Cancer Res 2002; 62:5076-82.
34. Kukushkin AN, Abramova MV, Svetlikova SB, Darieva ZA, Pospelova TV, Pospelov VA. Downregulation of c-fos gene transcription in cells transformed by E1A and cHa-ras oncogenes: A role of sustained activation of MAP/ERK kinase cascade and of inactive chromatin structure at c-fos promoter. Oncogene 2002; 21:719-30.
35. Chiou SK, White E. P300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. J Virol 1997; 71:3515-25.
36. Zhan Q, Kontny U, Iglesias M, Alamo I Jr, Yu K, Hollander MC, Woodworth CD, Fornace AJ Jr. Inhibitory effect of Bcl-2 on p53-mediated transactivation following genotoxic stress. Oncogene 1999; 18:297-304.
37. De Moissac D, Mustapha S, Greenberg AH, Kirshenbaum LA. Bcl-2 activates the transcription factor NF-κB through the degradation of the cytoplasmic inhibitor IkB. J Biol Chem 1998; 273:23946-51.
38. Ivanov VN, Deng G, Podack ER, Malek TR. Pleiotropic effects of Bcl-2 on transcription factors in T cells: Potential role of NF-κB p50-p50 for the anti-apoptotic function of Bcl-2. Int Immunol 1995; 7:1709-20.
39. Blagosklonny MV. Cell senescence and hypermitogenic arrest. EMBO Rep 2003; 4:358-62.
40. Schmitt CA, Fridman JS, Yang M, Lee S, Batanov E, Hoffman RM, Lowe SW. A senescence program controlled by p53 and p16 INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46.